Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.
about
Antibody Subclass Repertoire and Graft Outcome Following Solid Organ TransplantationGene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes.Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute RejectionUnderstanding Medication Nonadherence after Kidney Transplant.Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypesMolecular assessment of disease states in kidney transplant biopsy samples.Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study.Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation.Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection.Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.Evolving Approaches in the Identification of Allograft-reactive T and B Cells in Mice and Humans.Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.Subclinical antibody-mediated rejection due to anti-human-leukocyte-antigen-DR53 antibody accompanied by plasma cell-rich acute rejection in a patient with cadaveric kidney transplantation.Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.Acute Rejection Phenotypes in the Current Era of Immunosuppression: A Single-Center Analysis.The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.Looking for the needle in the kidney transplantation haystack.Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice.Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation: Delayed CTLA4-Ig Treatment Prevents Memory Alloreactive B-Cell Generation.Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study.Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.A molecular biopsy test based on arteriolar under-hyalinosis reflects increased probability of rejection related to under-immunosuppression.Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.Selective CD28 Blockade Results in Superior Inhibition of Donor-Specific T Follicular Helper Cell and Antibody Responses Relative to CTLA4-Ig.De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis.Being Thoughtful about Desensitization.Heterogeneity of memory B cells.A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity.Incidence, Characterization and Impact of Newly Detected Donor Specific Anti-HLA Antibody in the First Year after Pediatric Heart Transplantation: A Report From the CTOTC-04 Study.Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study.The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion.Utility of protocol kidney biopsies for de novo donor-specific antibodies.CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression.Using Molecular Phenotyping to Guide Improvements in the Histologic Diagnosis of T Cell-Mediated Rejection.Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
P2860
Q28076193-FDA04804-AD09-476E-BC6E-6777ECFBECDFQ33885388-92C573A5-4549-4A22-BDED-C63351DC2DAAQ37601515-155242D9-37E0-4BC2-BF6D-19F2C4746047Q38416698-F7D39CF3-7A0C-4850-A691-100FC21E56F4Q38718380-D5682300-68C8-45EE-BB19-293C76604FB4Q38725625-816F9388-65A4-4EDE-A191-23CBD446664FQ38877380-0ED77DEB-7EDE-4D2F-87D8-B800AFD37693Q38967641-B18F8F12-E38E-44B9-8D50-E5931FCB0770Q39207543-850F669F-176B-4AE5-AC64-E4FA84E15A3CQ39217968-178B2977-B9A7-418D-91C0-D1649ACC0D8FQ39366396-AA609D8A-034D-4841-99AA-B6A613BA17B9Q39366464-E6004F1E-7611-47C3-8B93-C15CD1C3EC29Q39512442-41F0E4F5-C3E8-4A36-B769-2CFA5A21D606Q40856776-C7B713B7-05AC-4E73-B0AE-A67EACC425E4Q41495990-F75245A0-45CB-4B84-9FDD-AA83740F7BC8Q41946081-3EDB1AE7-3C83-4486-93F4-AACF6E542795Q42174325-406E20D4-27AA-4DC3-A31C-A089E657BF60Q42204915-F9DE55E9-7243-482E-AC70-2BF20E89D323Q42362413-A1D756F4-8FF7-4EC9-A60B-26DE7F824AF3Q42402671-5B3A6D75-BAAD-4DBD-878E-F077F08BF7DBQ45057936-4AA9E97F-72C5-4BE9-9CC2-8661FB4A68B5Q46409439-A3A4E628-BD1F-45D0-9932-B2B02FC4F215Q47292306-30116DDD-3ED4-416E-B129-5FAC5A4CED08Q47754574-95394554-7C58-415D-AC07-9CEB33BB5173Q47850607-DB77A085-C2E4-4803-83D9-3AB73A7EBA84Q47920746-C9CC3CD0-DFE6-4867-A548-D4FC9266B335Q48747887-5158DC62-D8AD-4E0F-BF7F-1804D6148ADFQ48955987-2CFC2B32-3420-4B62-B9C5-6A041C061217Q49643119-5C5FC01C-8557-44A9-9FE3-8C3B6664998CQ49852352-F017C8A0-FA27-4D13-8F68-D25158FF619DQ49925863-02AF5745-0785-4B92-84B8-450F4A488762Q50015757-D2EE6047-547C-4AFA-BE74-5000A6ECD31DQ50016560-AD78A021-CEFA-48B4-9959-C4793239F17DQ50193450-3AE87EA2-CFB9-49AC-80C1-54BE8D6A258BQ50504222-C7D8BFDD-CA26-4714-B3CB-2891FF38E899Q50531944-19AACCBE-515C-4E74-8224-F37B5E7C964BQ50743724-A4DA5C6D-1C97-45A6-A32C-86BC681EF03DQ50879242-60068499-B6C2-487E-BEC2-D1658EE24D61Q51010023-2E9DDEB4-5F3F-42F5-9BF8-303E87C54BDBQ51563025-F9D61C21-6619-4773-A8E2-0C0687BE1E9E
P2860
Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Rates and determinants of prog ...... novo donor-specific antibody.
@en
Rates and determinants of prog ...... novo donor-specific antibody.
@nl
type
label
Rates and determinants of prog ...... novo donor-specific antibody.
@en
Rates and determinants of prog ...... novo donor-specific antibody.
@nl
prefLabel
Rates and determinants of prog ...... novo donor-specific antibody.
@en
Rates and determinants of prog ...... novo donor-specific antibody.
@nl
P2093
P2860
P50
P356
P1476
Rates and determinants of prog ...... novo donor-specific antibody.
@en
P2093
A Goldberg
D Pochinco
I W Gibson
L Storsley
M Karpinski
P W Nickerson
P2860
P304
P356
10.1111/AJT.13347
P407
P577
2015-06-10T00:00:00Z